Fig. 6.
Kaplan–Meier analysis of overall (a) and progression-free survival (b) in subgroup analysis comparing the efficacy of camrelizumab and sintilimab. HR hazard ratio
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.